Wells Fargo & Company MN Buys 2,678 Shares of Inari Medical, Inc. (NASDAQ:NARI)

Wells Fargo & Company MN raised its stake in shares of Inari Medical, Inc. (NASDAQ:NARI) by 2.6% in the 4th quarter, according to its most recent disclosure with the SEC. The firm owned 105,742 shares of the company’s stock after purchasing an additional 2,678 shares during the period. Wells Fargo & Company MN’s holdings in Inari Medical were worth $5,398,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of the stock. Motley Fool Asset Management LLC grew its stake in shares of Inari Medical by 10.4% during the 4th quarter. Motley Fool Asset Management LLC now owns 62,872 shares of the company’s stock valued at $3,210,000 after acquiring an additional 5,913 shares during the period. Bryce Point Capital LLC bought a new position in shares of Inari Medical in the fourth quarter worth approximately $533,000. Trexquant Investment LP increased its stake in shares of Inari Medical by 21.2% in the fourth quarter. Trexquant Investment LP now owns 172,520 shares of the company’s stock worth $8,807,000 after purchasing an additional 30,167 shares in the last quarter. Franklin Resources Inc. raised its position in shares of Inari Medical by 1.2% during the 4th quarter. Franklin Resources Inc. now owns 226,580 shares of the company’s stock valued at $11,567,000 after purchasing an additional 2,770 shares during the period. Finally, Pictet Asset Management Holding SA lifted its stake in shares of Inari Medical by 12.9% during the 4th quarter. Pictet Asset Management Holding SA now owns 7,935 shares of the company’s stock valued at $405,000 after buying an additional 909 shares in the last quarter. Hedge funds and other institutional investors own 90.98% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have issued reports on NARI. Robert W. Baird reiterated a “neutral” rating and issued a $80.00 price target (down previously from $81.00) on shares of Inari Medical in a research note on Tuesday, January 7th. BTIG Research reissued a “neutral” rating on shares of Inari Medical in a research note on Wednesday, January 8th. William Blair restated a “market perform” rating on shares of Inari Medical in a research note on Tuesday, January 7th. Wells Fargo & Company reiterated an “equal weight” rating and set a $80.00 price objective (up previously from $65.00) on shares of Inari Medical in a research report on Tuesday, January 7th. Finally, Piper Sandler upped their target price on shares of Inari Medical from $52.00 to $80.00 and gave the stock a “neutral” rating in a research report on Tuesday, January 7th. Twelve analysts have rated the stock with a hold rating and two have issued a buy rating to the company. Based on data from MarketBeat, Inari Medical presently has a consensus rating of “Hold” and a consensus price target of $68.00.

Inari Medical Price Performance

Shares of NASDAQ:NARI opened at $79.97 on Friday. The firm has a fifty day simple moving average of $79.97 and a two-hundred day simple moving average of $65.64. Inari Medical, Inc. has a 52 week low of $36.73 and a 52 week high of $79.99. The stock has a market capitalization of $4.68 billion, a P/E ratio of -59.24 and a beta of 1.02.

About Inari Medical

Inari Medical, Inc builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation.